GenScript Biotech

GenCrispr Cas9 Nuclease is the recombinant Streptococcus pyogenes
Cas9 (wt) protein purified from E. coli and can be used for genome editing by inducing site-specific double stranded breaks in double stranded DNA. Cas9 protein forms a very stable ribonucleoprotein (RNP) complex with the guide RNA (gRNA) component of the CRISPR/Cas9 system. The RNP complex recognizes the target site by matching gRNA with the genomic DNA sequence and leads to DNA breaks within 3 bases from the NGG PAM (Protospacer Adjacent Motif). With GenCrispr Cas9 nuclease, customers can screen highly efficient gRNA using in vitro
DNA cleavage assays. It could be a powerful tool for gene editing.

Product Source :
GenCrispr Cas9 Nuclease is produced by expression in an
E. coli
strain carrying a plasmid encoding the Cas9 gene from
Streptococcus pyogenes
without nuclear localization signal (NLS).

With this Cas9 Nuclease, you can:

1. Screening for highly efficient and specific targeting gRNAs by
   in vitro
   DNA cleavage using Cas9 Nuclease from
   S. pyogenes
   (
   please find the detailed protocol in the product manual
   ).

2. Highly purified Cas9 antigen could be used for specific antibody production.

GenCrispr Cas9 Nuclease is the recombinant Streptococcus pyogenes
Cas9 (wt) protein purified from E. coli and can be used for genome editing by inducing site-specific double stranded breaks in double stranded DNA. Cas9 protein forms a very stable ribonucleoprotein (RNP) complex with the guide RNA (gRNA) component of the CRISPR/Cas9 system. The RNP complex recognizes the target site by matching gRNA with the genomic DNA sequence and leads to DNA breaks within 3 bases from the NGG PAM (Protospacer Adjacent Motif). With GenCrispr Cas9 nuclease, customers can screen highly efficient gRNA using in vitro
DNA cleavage assays. It could be a powerful tool for gene editing.

Product Source :
GenCrispr Cas9 Nuclease is produced by expression in an
E. coli
strain carrying a plasmid encoding the Cas9 gene from
Streptococcus pyogenes
without nuclear localization signal (NLS).

With this Cas9 Nuclease, you can:

1. Screening for highly efficient and specific targeting gRNAs by
   in vitro
   DNA cleavage using Cas9 Nuclease from
   S. pyogenes
   (
   please find the detailed protocol in the product manual
   ).

2. Highly purified Cas9 antigen could be used for specific antibody production.

GenCrispr Cas9-C-NLS nuclease is the recombinant Streptococcus pyogenes
Cas9 (wt) protein with a C-terminal nucleic localization signal (NLS) that can be used for genome editing by inducing site-specific DNA double stranded breaks. Cas9 protein forms a very stable ribonucleoprotein (RNP) complex with the guide RNA (gRNA) component of the CRISPR/Cas9 system, which can localize to the nucleus immediately once entering the cell with the guide of the NLS. Compared with the mRNA or plasmid systems, transcription and translation processes are not required. This DNA-free system avoids the risk of inserting foreign DNA into the genome, which can be quite useful for gene editing-based disease therapy. Our highly pure and active Cas9 nuclease meets all of the researcher’s requirements (e.g. in vitro
cleavage assay, RNP complex transfection, micro injection).

Product Source:
GenCrispr Cas9-C-NLS is produced by expression in an
E. coli
strain carrying a plasmid encoding the Cas9 gene from
Streptococcus pyogenes
with a C terminal nuclear localization signal (NLS).

Key features:

• DNA-free: no external DNA added to system.
• High cleavage efficiency: NLS ensures the entry of Cas9 protein into nuclei.
• Low off target: transient expression of Cas9 nuclease.
• Time-saving: no need for transcription and translation.

With this Cas9 Nuclease, you can:

1. Screening the highly efficient and specific targeting gRNAs using
   in vitro
   DNA cleavage.
2. In vivo
   gene editing combined with specific gRNA by electroporation or injection.

GenCrispr Cas9-C-NLS nuclease is the recombinant Streptococcus pyogenes
Cas9 (wt) protein with a C-terminal nucleic localization signal (NLS) that can be used for genome editing by inducing site-specific DNA double stranded breaks. Cas9 protein forms a very stable ribonucleoprotein (RNP) complex with the guide RNA (gRNA) component of the CRISPR/Cas9 system, which can localize to the nucleus immediately once entering the cell with the guide of the NLS. Compared with the mRNA or plasmid systems, transcription and translation processes are not required. This DNA-free system avoids the risk of inserting foreign DNA into the genome, which can be quite useful for gene editing-based disease therapy. Our highly pure and active Cas9 nuclease meets all of the researcher’s requirements (e.g. in vitro
cleavage assay, RNP complex transfection, micro injection).

Product Source:
GenCrispr Cas9-C-NLS is produced by expression in an
E. coli
strain carrying a plasmid encoding the Cas9 gene from
Streptococcus pyogenes
with a C terminal nuclear localization signal (NLS).

Key features:

• DNA-free: no external DNA added to system.
• High cleavage efficiency: NLS ensures the entry of Cas9 protein into nuclei.
• Low off target: transient expression of Cas9 nuclease.
• Time-saving: no need for transcription and translation.

With this Cas9 Nuclease, you can:

1. Screening the highly efficient and specific targeting gRNAs using
   in vitro
   DNA cleavage.
2. In vivo
   gene editing combined with specific gRNA by electroporation or injection.

GenCrispr Cas9-N-NLS nuclease is the recombinant Streptococcus pyogenes Cas9 (wt) protein with a N-terminal nucleic localization signal (NLS) that can be used for genome editing by inducing site-specific DNA double stranded breaks. Cas9 protein forms a very stable ribonucleoprotein (RNP) complex with the guide RNA (gRNA) component of the CRISPR/Cas9 system, which can localize to the nucleus immediately once entering the cell with the guide of the NLS. Compared with the mRNA or plasmid systems, transcription and translation processes are not required. This DNA-free system avoids the risk of inserting foreign DNA into the genome, which can be quite useful for gene editing-based disease therapy. Our highly pure and active Cas9 nuclease meets all of the researcher´s requirements (e.g. in vitro cleavage assay, RNP complex transfection, micro injection).

Product Source: GenCrispr Cas9-N-NLS is produced by expression in an E. coli strain carrying a plasmid encoding the Cas9 gene from Streptococcus pyogenes with a N-terminal nuclear localization signal (NLS).

Key features:

• DNA-free: no external DNA added to system.
• High cleavage efficiency: NLS ensures the entry of Cas9 protein into nuclei.
• Low off target: transient expression of Cas9 nuclease.
• Time-saving: no need for transcription and translation.

With this Cas9 Nuclease, you can:

1. Screening the highly efficient and specific targeting gRNAs using in vitro DNA cleavage.
2. In vivo gene editing combined with specific gRNA by electroporation or injection.

GenCrispr Cas9-N-NLS nuclease is the recombinant Streptococcus pyogenes Cas9 (wt) protein with a N-terminal nucleic localization signal (NLS) that can be used for genome editing by inducing site-specific DNA double stranded breaks. Cas9 protein forms a very stable ribonucleoprotein (RNP) complex with the guide RNA (gRNA) component of the CRISPR/Cas9 system, which can localize to the nucleus immediately once entering the cell with the guide of the NLS. Compared with the mRNA or plasmid systems, transcription and translation processes are not required. This DNA-free system avoids the risk of inserting foreign DNA into the genome, which can be quite useful for gene editing-based disease therapy. Our highly pure and active Cas9 nuclease meets all of the researcher´s requirements (e.g. in vitro cleavage assay, RNP complex transfection, micro injection).

Product Source: GenCrispr Cas9-N-NLS is produced by expression in an E. coli strain carrying a plasmid encoding the Cas9 gene from Streptococcus pyogenes with a N-terminal nuclear localization signal (NLS).

Key features:

• DNA-free: no external DNA added to system.
• High cleavage efficiency: NLS ensures the entry of Cas9 protein into nuclei.
• Low off target: transient expression of Cas9 nuclease.
• Time-saving: no need for transcription and translation.

With this Cas9 Nuclease, you can:

1. Screening the highly efficient and specific targeting gRNAs using in vitro DNA cleavage.
2. In vivo gene editing combined with specific gRNA by electroporation or injection.

Cas9 nuclease is an RNA-guided endonuclease that can catalyze cleavage of double stranded DNA. This kind of targeted nuclease is a powerful tool for genome editing with high precision. Cas9 protein forms a very stable ribonucleoprotein (RNP) complex with the guide RNA (gRNA) component of the CRISPR/Cas9 system. The Cas9 RNP complex can localize to the nucleus immediately upon entering the cell with the addition of a nuclear localization signal (NLS). There is no requirement for transcription and translation compared with mRNA or plasmid systems. Additionally, the Cas9 RNP complex is rapidly cleared from the cell minimizing the chance of off-target cleavage when compared to other systems (Kim, et al. 2014). This DNA-free system avoids the risk of inserting foreign DNA into the genome, which can be quite useful for gene editing-based disease therapy. GenScript has developed a Cas9-N-NLS nuclease which contains a nuclear localization sequence (NLS) on the N-terminus of the protein to meet all the researchers’ requirements (e.g. in vitro cleavage assay, RNP complex transfection, and micro injection).

Product Source:GenCrispr Cas9-N-NLS is produced by expression in an E. coli strain carrying a plasmid encoding the Cas9 gene from Streptococcus pyogenes with a N terminal nuclear localization signal (NLS).

Key Features

-DNA-free: no external DNA added to system

-High cleavage efficiency: NLS ensures the entry of Cas9 protein into nuclei

-Low off target: transient expression of Cas9 nuclease

-Time-saving: no need for transcription and translation

Applications

-Screening for highly efficient and specific targeting gRNAs by in vitro DNA cleavage.

–In vivo gene editing when combined with a specific gRNA by electroporation or injection.

Cas9 nuclease is an RNA-guided endonuclease that can catalyze cleavage of double stranded DNA. This kind of targeted nuclease is a powerful tool for genome editing with high precision. Cas9 protein forms a very stable ribonucleoprotein (RNP) complex with the guide RNA (gRNA) component of the CRISPR/Cas9 system. The Cas9 RNP complex can localize to the nucleus immediately upon entering the cell with the addition of a nuclear localization signal (NLS). There is no requirement for transcription and translation compared with mRNA or plasmid systems. Additionally, the Cas9 RNP complex is rapidly cleared from the cell minimizing the chance of off-target cleavage when compared to other systems (Kim, et al. 2014). This DNA-free system avoids the risk of inserting foreign DNA into the genome, which can be quite useful for gene editing-based disease therapy. GenScript has developed a Cas9-N-NLS nuclease which contains a nuclear localization sequence (NLS) on the N-terminus of the protein to meet all the researchers’ requirements (e.g. in vitro cleavage assay, RNP complex transfection, and micro injection).

Product Source:GenCrispr Cas9-N-NLS is produced by expression in an E. coli strain carrying a plasmid encoding the Cas9 gene from Streptococcus pyogenes with a N terminal nuclear localization signal (NLS).

Key Features

-DNA-free: no external DNA added to system

-High cleavage efficiency: NLS ensures the entry of Cas9 protein into nuclei

-Low off target: transient expression of Cas9 nuclease

-Time-saving: no need for transcription and translation

Applications

-Screening for highly efficient and specific targeting gRNAs by in vitro DNA cleavage.

–In vivo gene editing when combined with a specific gRNA by electroporation or injection.

Cas9 nuclease is an RNA-guided endonuclease that can catalyze cleavage of double stranded DNA. This kind of targeted nuclease is a powerful tool for genome editing with high precision. Cas9 protein forms a very stable ribonucleoprotein (RNP) complex with the guide RNA (gRNA) component of the CRISPR/Cas9 system. The Cas9 RNP complex can localize to the nucleus immediately upon entering the cell with the addition of a nuclear localization signal (NLS). There is no requirement for transcription and translation compared with mRNA or plasmid systems. Additionally, the Cas9 RNP complex is rapidly cleared from the cell minimizing the chance of off-target cleavage when compared to other systems (Kim, et al. 2014). This DNA-free system avoids the risk of inserting foreign DNA into the genome, which can be quite useful for gene editing-based disease therapy. GenScript has developed a Cas9-N-NLS nuclease which contains a nuclear localization sequence (NLS) on the N-terminus of the protein to meet all the researchers’ requirements (e.g. in vitro cleavage assay, RNP complex transfection, and micro injection).

Product Source:GenCrispr Cas9-N-NLS is produced by expression in an E. coli strain carrying a plasmid encoding the Cas9 gene from Streptococcus pyogenes with a N terminal nuclear localization signal (NLS).

Key Features

-DNA-free: no external DNA added to system

-High cleavage efficiency: NLS ensures the entry of Cas9 protein into nuclei

-Low off target: transient expression of Cas9 nuclease

-Time-saving: no need for transcription and translation

Applications

-Screening for highly efficient and specific targeting gRNAs by in vitro DNA cleavage.

–In vivo gene editing when combined with a specific gRNA by electroporation or injection.

GenCrispr eSpCas9 nuclease is a mutant form of Cas9 nuclease. Cas9 nuclease is an RNA-guided endonuclease that can catalyze cleavage of double stranded DNA. This kind of targeted nuclease is a powerful tool for genome editing with high precision. Cas9 protein forms a very stable ribonucleoprotein (RNP) complex with the guide RNA (gRNA) component of the CRISPR/Cas9system. Compared with the wild type Cas9 nuclease, eSpCas9 reduces off-target effects by over 10-fold, while maintaining robust on-target genome editing efficiency. GenScript has developed a eSpCas9-N-NLS nuclease which contains a nuclear localization sequence (NLS) on the N-terminus of the protein to meet all the researchers’ requirements (e.g. in vitro cleavage assay, RNP complex transfection, and micro injection).

Product Source: GenCrispr eSpCas9-N-NLS is produced by expression in an E. coli strain carrying a plasmid encoding the Cas9 gene from Streptococcus pyogenes with a N terminal nuclear localization signal (NLS).

Key Features

-DNA-free: no external DNA added to system

-High cleavage efficiency: NLS ensures the entry of Cas9 protein into nuclei

-Low off target: transient expression of Cas9 nuclease

-Time-saving: no need for transcription and translation

Applications

-Screening for highly efficient and specific targeting gRNAs by in vitro DNA cleavage.

–In vivo gene editing when combined with a specific gRNA by electroporation or injection.

GenCrispr eSpCas9 nuclease is a mutant form of Cas9 nuclease. Cas9 nuclease is an RNA-guided endonuclease that can catalyze cleavage of double stranded DNA. This kind of targeted nuclease is a powerful tool for genome editing with high precision. Cas9 protein forms a very stable ribonucleoprotein (RNP) complex with the guide RNA (gRNA) component of the CRISPR/Cas9system. Compared with the wild type Cas9 nuclease, eSpCas9 reduces off-target effects by over 10-fold, while maintaining robust on-target genome editing efficiency. GenScript has developed a eSpCas9-N-NLS nuclease which contains a nuclear localization sequence (NLS) on the N-terminus of the protein to meet all the researchers’ requirements (e.g. in vitro cleavage assay, RNP complex transfection, and micro injection).

Product Source: GenCrispr eSpCas9-N-NLS is produced by expression in an E. coli strain carrying a plasmid encoding the Cas9 gene from Streptococcus pyogenes with a N terminal nuclear localization signal (NLS).

Key Features

-DNA-free: no external DNA added to system

-High cleavage efficiency: NLS ensures the entry of Cas9 protein into nuclei

-Low off target: transient expression of Cas9 nuclease

-Time-saving: no need for transcription and translation

Applications

-Screening for highly efficient and specific targeting gRNAs by in vitro DNA cleavage.

–In vivo gene editing when combined with a specific gRNA by electroporation or injection.

GenCrispr NLS-Cas9-D10A Nickase is a mutation form of Cas9 Nuclease. Cas9 nuclease is an RNA-guided endonuclease that can catalyze cleavage of double stranded DNA. This kind of targeted nuclease is a powerful tool for genome editing with high precision. Cas9 nuclease cleaves the double strand DNA generating two break sites based on its two active domains. NLS-Cas9-D10A Nickase is a mutation form of Cas9 Nuclease which makes one active domain deactivated, thus it can only cut one single strand DNA that is complementary to the guide-RNA, producing one single strand cut. Combined with two different gRNA, NLS-Cas9-D10A Nickase produces two cut sites respectively and causes a double strand break. Compared with the wild type Cas9 nuclease, the two-gRNA guided cleavage can significantly reduce the off target effects.

Product Source: GenCripsr NLS-Cas9-D10A Nickase is highly purified mutant proteins expressed in an E. coli strain carrying a plasmid encoding the mutated Cas9 gene from Streptococcus pyogenes.

Key features:

• DNA-free: no external DNA added to system.
• High cleavage efficiency: NLS ensures the efficient entry of Cas9 protein into nuclei.
• Low off target: Double gRNA-guided cleavage and transient expression of Cas9 nuclease.
• Time-saving: no need for transcription and translation.

With this Cas9 Nuclease, you can:

1. Screening the highly efficient and specific targeting gRNAs using in vitro DNA cleavage.
2. In vivo gene editing combined with specific gRNA by electroporation or injection.

GenCrispr NLS-Cas9-D10A Nickase is a mutation form of Cas9 Nuclease. Cas9 nuclease is an RNA-guided endonuclease that can catalyze cleavage of double stranded DNA. This kind of targeted nuclease is a powerful tool for genome editing with high precision. Cas9 nuclease cleaves the double strand DNA generating two break sites based on its two active domains. NLS-Cas9-D10A Nickase is a mutation form of Cas9 Nuclease which makes one active domain deactivated, thus it can only cut one single strand DNA that is complementary to the guide-RNA, producing one single strand cut. Combined with two different gRNA, NLS-Cas9-D10A Nickase produces two cut sites respectively and causes a double strand break. Compared with the wild type Cas9 nuclease, the two-gRNA guided cleavage can significantly reduce the off target effects.

Product Source: GenCripsr NLS-Cas9-D10A Nickase is highly purified mutant proteins expressed in an E. coli strain carrying a plasmid encoding the mutated Cas9 gene from Streptococcus pyogenes.

Key features:

• DNA-free: no external DNA added to system.
• High cleavage efficiency: NLS ensures the efficient entry of Cas9 protein into nuclei.
• Low off target: Double gRNA-guided cleavage and transient expression of Cas9 nuclease.
• Time-saving: no need for transcription and translation.

With this Cas9 Nuclease, you can:

1. Screening the highly efficient and specific targeting gRNAs using in vitro DNA cleavage.
2. In vivo gene editing combined with specific gRNA by electroporation or injection.

GenCrispr NLS-Cas9-D10A Nickase is a mutation form of Cas9 Nuclease. Cas9 nuclease is an RNA-guided endonuclease that can catalyze cleavage of double stranded DNA. This kind of targeted nuclease is a powerful tool for genome editing with high precision. Cas9 nuclease cleaves the double strand DNA generating two break sites based on its two active domains. NLS-Cas9-D10A Nickase is a mutation form of Cas9 Nuclease which makes one active domain deactivated, thus it can only cut one single strand DNA that is complementary to the guide-RNA, producing one single strand cut. Combined with two different gRNA, NLS-Cas9-D10A Nickase produces two cut sites respectively and causes a double strand break. Compared with the wild type Cas9 nuclease, the two-gRNA guided cleavage can significantly reduce the off target effects.

Product Source: GenCripsr NLS-Cas9-D10A Nickase is highly purified mutant proteins expressed in an E. coli strain carrying a plasmid encoding the mutated Cas9 gene from Streptococcus pyogenes.

Key features:

• DNA-free: no external DNA added to system.
• High cleavage efficiency: NLS ensures the efficient entry of Cas9 protein into nuclei.
• Low off target: Double gRNA-guided cleavage and transient expression of Cas9 nuclease.
• Time-saving: no need for transcription and translation.

With this Cas9 Nuclease, you can:

1. Screening the highly efficient and specific targeting gRNAs using in vitro DNA cleavage.
2. In vivo gene editing combined with specific gRNA by electroporation or injection.

GenCrispr NLS-Cas9-EGFP is a fusion protein developed by GenScript. It contains a nuclear localization signal (NLS) on its N terminal end, and an EGFP and a 6x(His) sequence on the C terminal end. Cas9 nuclease is an RNA-guided endonuclease that can catalyze cleavage of double stranded DNA. This kind of targeted nuclease is a powerful tool for genome editing with high precision. Cas9 protein forms a highly stable ribonucleoprotein (RNP) complex with the guide RNA (gRNA) component of the CRISPR/Cas9 system. When Cas9 is expressed with an NLS sequence, the Cas9 RNP complex can localize to the nucleus immediately upon entering the cell. There is no requirement for in vivo transcription or translation, which improves the efficiency of this method over plasmid-based systems. Additionally, the Cas9 RNP complex is rapidly cleared from the cells minimizing the chance of off-target cleavage when compared to other systems (Kim, et al. 2014). The EGFP tag can be used as a reporter for tracking or sorting transfected cells, which enables enrichment of cell populations for desired genome edits via fluorescence activated cell sorting (FACS). It significantly reduces the labor and cost associated with single cell cloning and genotyping in genome editing applications. 

Product Source: GenCrispr NLS-Cas9-EGFP is produced by expression from an E. coli strain.

Key Features

– DNA-free: no external DNA added to system
– High cleavage efficiency: NLS ensures the efficient entry of the Cas9 protein into nuclei
– Low off target effects: transient expression of Cas9 nuclease improves specificity of cleavage
– Time-saving: no need for transcription and translation
– Reduced labor: enrich cell populations for desired genome edits via EGFP-based FACS. The C-terminal His-tag increases the choice of detection methods for the fusion protein.

Applications

– Screening for highly efficient and specific targeting gRNAs by in vitro DNA cleavage.
– In vivo gene editing when combined with a specific gRNA by electroporation or injection.
– Enrichment of cell populations for desired genome edits via EGFP-based FACS.

GenCrispr NLS-Cas9-EGFP is a fusion protein developed by GenScript. It contains a nuclear localization signal (NLS) on its N terminal end, and an EGFP and a 6x(His) sequence on the C terminal end. Cas9 nuclease is an RNA-guided endonuclease that can catalyze cleavage of double stranded DNA. This kind of targeted nuclease is a powerful tool for genome editing with high precision. Cas9 protein forms a highly stable ribonucleoprotein (RNP) complex with the guide RNA (gRNA) component of the CRISPR/Cas9 system. When Cas9 is expressed with an NLS sequence, the Cas9 RNP complex can localize to the nucleus immediately upon entering the cell. There is no requirement for in vivo transcription or translation, which improves the efficiency of this method over plasmid-based systems. Additionally, the Cas9 RNP complex is rapidly cleared from the cells minimizing the chance of off-target cleavage when compared to other systems (Kim, et al. 2014). The EGFP tag can be used as a reporter for tracking or sorting transfected cells, which enables enrichment of cell populations for desired genome edits via fluorescence activated cell sorting (FACS). It significantly reduces the labor and cost associated with single cell cloning and genotyping in genome editing applications. 

Product Source: GenCrispr NLS-Cas9-EGFP is produced by expression from an E. coli strain.

Key Features

– DNA-free: no external DNA added to system
– High cleavage efficiency: NLS ensures the efficient entry of the Cas9 protein into nuclei
– Low off target effects: transient expression of Cas9 nuclease improves specificity of cleavage
– Time-saving: no need for transcription and translation
– Reduced labor: enrich cell populations for desired genome edits via EGFP-based FACS. The C-terminal His-tag increases the choice of detection methods for the fusion protein.

Applications

– Screening for highly efficient and specific targeting gRNAs by in vitro DNA cleavage.
– In vivo gene editing when combined with a specific gRNA by electroporation or injection.
– Enrichment of cell populations for desired genome edits via EGFP-based FACS.

GenCrispr NLS-Cas9-EGFP is a fusion protein developed by GenScript. It contains a nuclear localization sequence (NLS) on its N terminal and EGFP on the C terminal. Cas9 nuclease is an RNA-guided endonuclease that can catalyze cleavage of double stranded DNA. This kind of targeted nuclease is a powerful tool for genome editing with high precision. Cas9 protein forms a very stable ribonucleoprotein (RNP) complex with the guide RNA (gRNA) component of the CRISPR/Cas9 system. The Cas9 RNP complex can localize to the nucleus immediately upon entering the cell with the addition of a nuclear localization signal (NLS). There is no requirement for transcription and translation compared with mRNA or plasmid systems. Additionally, the Cas9 RNP complex is rapidly cleared from the cells minimizing the chance of off-target cleavage when compared to other systems (Kim, et al. 2014). The EGFP can be used as a reporter for tracking or sorting transfected cells, which enables the possibility of enriching cell populations for desired genome edits via fluorescence activated cell sorting (FACS). It significantly reduces the labor and cost associated with single cell cloning and genotyping in genome editing applications.

Product Source: GenCrispr NLS-Cas9-EGFP is produced by expression from an E. coli strain.

Key Features

-DNA-free: no external DNA added to system

-High cleavage efficiency: NLS ensures the entry of Cas9 protein into nuclei

-Low off target: transient expression of Cas9 nuclease

-Time-saving: no need for transcription and translation

Applications

-Screening for highly efficient and specific targeting gRNAs by in vitro DNA cleavage.

– In vivo gene editing when combined with a specific gRNA by electroporation or injection.

GenCrispr NLS-Cas9-EGFP is a fusion protein developed by GenScript. It contains a nuclear localization sequence (NLS) on its N terminal and EGFP on the C terminal. Cas9 nuclease is an RNA-guided endonuclease that can catalyze cleavage of double stranded DNA. This kind of targeted nuclease is a powerful tool for genome editing with high precision. Cas9 protein forms a very stable ribonucleoprotein (RNP) complex with the guide RNA (gRNA) component of the CRISPR/Cas9 system. The Cas9 RNP complex can localize to the nucleus immediately upon entering the cell with the addition of a nuclear localization signal (NLS). There is no requirement for transcription and translation compared with mRNA or plasmid systems. Additionally, the Cas9 RNP complex is rapidly cleared from the cells minimizing the chance of off-target cleavage when compared to other systems (Kim, et al. 2014). The EGFP can be used as a reporter for tracking or sorting transfected cells, which enables the possibility of enriching cell populations for desired genome edits via fluorescence activated cell sorting (FACS). It significantly reduces the labor and cost associated with single cell cloning and genotyping in genome editing applications.

Product Source: GenCrispr NLS-Cas9-EGFP is produced by expression from an E. coli strain.

Key Features

-DNA-free: no external DNA added to system

-High cleavage efficiency: NLS ensures the entry of Cas9 protein into nuclei

-Low off target: transient expression of Cas9 nuclease

-Time-saving: no need for transcription and translation

Applications

-Screening for highly efficient and specific targeting gRNAs by in vitro DNA cleavage.

– In vivo gene editing when combined with a specific gRNA by electroporation or injection.

GenCrispr NLS-Cas9-EGFP is a fusion protein developed by GenScript. It contains a nuclear localization sequence (NLS) on its N terminal and EGFP on the C terminal. Cas9 nuclease is an RNA-guided endonuclease that can catalyze cleavage of double stranded DNA. This kind of targeted nuclease is a powerful tool for genome editing with high precision. Cas9 protein forms a very stable ribonucleoprotein (RNP) complex with the guide RNA (gRNA) component of the CRISPR/Cas9 system. The Cas9 RNP complex can localize to the nucleus immediately upon entering the cell with the addition of a nuclear localization signal (NLS). There is no requirement for transcription and translation compared with mRNA or plasmid systems. Additionally, the Cas9 RNP complex is rapidly cleared from the cells minimizing the chance of off-target cleavage when compared to other systems (Kim, et al. 2014). The EGFP can be used as a reporter for tracking or sorting transfected cells, which enables the possibility of enriching cell populations for desired genome edits via fluorescence activated cell sorting (FACS). It significantly reduces the labor and cost associated with single cell cloning and genotyping in genome editing applications.

Product Source: GenCrispr NLS-Cas9-EGFP is produced by expression from an E. coli strain.

Key Features

-DNA-free: no external DNA added to system

-High cleavage efficiency: NLS ensures the entry of Cas9 protein into nuclei

-Low off target: transient expression of Cas9 nuclease

-Time-saving: no need for transcription and translation

Applications

-Screening for highly efficient and specific targeting gRNAs by in vitro DNA cleavage.

– In vivo gene editing when combined with a specific gRNA by electroporation or injection.

GenCrispr NLS-Cas9-NLS nuclease is the recombinant Streptococcus pyogenes Cas9 (wt) protein with a nucleic localization signal (NLS) on both N and C terminal, which can be used for genome editing by inducing site-specific DNA double stranded breaks. Cas9 protein forms a very stable ribonucleoprotein (RNP) complex with the guide RNA (gRNA) component of the CRISPR/Cas9 system, which can localize to the nucleus immediately once entering the cell with the guide of the NLS. Compared with the mRNA or plasmid systems, transcription and translation processes are not required. This DNA-free system avoids the risk of inserting foreign DNA into the genome, which can be quite useful for gene editing-based disease therapy. Our highly pure and active Cas9 nuclease meets all of the researcher´s requirements (e.g. in vitro cleavage assay, RNP complex transfection, micro injection).

Product Source: GenCrispr NLS-Cas9-NLS is produced by expression in an E. coli strain carrying a plasmid encoding the Cas9 gene from Streptococcus pyogenes with a double-ends nuclear localization signal (NLS).

Key features:

• DNA-free: no external DNA added to system.
• High cleavage efficiency: Double NLS ensures the efficient entry of Cas9 protein into nuclei.
• Low off target: transient expression of Cas9 nuclease.
• Time-saving: no need for transcription and translation.

With this Cas9 Nuclease, you can:

1. Screening the highly efficient and specific targeting gRNAs using in vitro DNA cleavage.
2. In vivo gene editing combined with specific gRNA by electroporation or injection.

GenCrispr NLS-Cas9-NLS nuclease is the recombinant Streptococcus pyogenes Cas9 (wt) protein with a nucleic localization signal (NLS) on both N and C terminal, which can be used for genome editing by inducing site-specific DNA double stranded breaks. Cas9 protein forms a very stable ribonucleoprotein (RNP) complex with the guide RNA (gRNA) component of the CRISPR/Cas9 system, which can localize to the nucleus immediately once entering the cell with the guide of the NLS. Compared with the mRNA or plasmid systems, transcription and translation processes are not required. This DNA-free system avoids the risk of inserting foreign DNA into the genome, which can be quite useful for gene editing-based disease therapy. Our highly pure and active Cas9 nuclease meets all of the researcher´s requirements (e.g. in vitro cleavage assay, RNP complex transfection, micro injection).

Product Source: GenCrispr NLS-Cas9-NLS is produced by expression in an E. coli strain carrying a plasmid encoding the Cas9 gene from Streptococcus pyogenes with a double-ends nuclear localization signal (NLS).

Key features:

• DNA-free: no external DNA added to system.
• High cleavage efficiency: Double NLS ensures the efficient entry of Cas9 protein into nuclei.
• Low off target: transient expression of Cas9 nuclease.
• Time-saving: no need for transcription and translation.

With this Cas9 Nuclease, you can:

1. Screening the highly efficient and specific targeting gRNAs using in vitro DNA cleavage.
2. In vivo gene editing combined with specific gRNA by electroporation or injection.

Cas9 nuclease is an RNA-guided endonuclease that can catalyze cleavage of double stranded DNA. This kind of targeted nuclease is a powerful tool for genome editing with high precision. Cas9 protein forms a very stable ribonucleoprotein (RNP) complex with the guide RNA (gRNA) component of the CRISPR/Cas9 system. The Cas9 RNP complex can localize to the nucleus immediately upon entering the cell with the addition of a nuclear localization signal (NLS). There is no requirement for transcription and translation compared with mRNA or plasmid systems. Additionally, the Cas9 RNP complex is rapidly cleared from the cell minimizing the chance of off-target cleavage when compared to other systems (Kim, et al. 2014). This DNA-free system avoids the risk of inserting foreign DNA into the genome, which can be quite useful for gene editing-based disease therapy. GenScript has developed a NLS-Cas9-NLS nuclease which contains a nuclear localization sequence (NLS) on both ends of the protein to meet all the researchers’ requirements (e.g. in vitro cleavage assay, RNP complex transfection, and micro injection).

Product Source: GenCrispr NLS-Cas9-NLS is produced by expression in an E. coli strain carrying a plasmid encoding the Cas9 gene from Streptococcus pyogenes with a nuclear localization signal (NLS) on both ends.

Key Features

-DNA-free: no external DNA added to system

-High cleavage efficiency: Double NLS ensures the efficient entry of Cas9 protein into nuclei

-Low off target: transient expression of Cas9 nuclease

Time-saving: no need for transcription and translation

Applications

-Screening for highly efficient and specific targeting gRNAs by in vitro DNA cleavage.

–In vivo gene editing when combined with a specific gRNA by electroporation or injection.

Cas9 nuclease is an RNA-guided endonuclease that can catalyze cleavage of double stranded DNA. This kind of targeted nuclease is a powerful tool for genome editing with high precision. Cas9 protein forms a very stable ribonucleoprotein (RNP) complex with the guide RNA (gRNA) component of the CRISPR/Cas9 system. The Cas9 RNP complex can localize to the nucleus immediately upon entering the cell with the addition of a nuclear localization signal (NLS). There is no requirement for transcription and translation compared with mRNA or plasmid systems. Additionally, the Cas9 RNP complex is rapidly cleared from the cell minimizing the chance of off-target cleavage when compared to other systems (Kim, et al. 2014). This DNA-free system avoids the risk of inserting foreign DNA into the genome, which can be quite useful for gene editing-based disease therapy. GenScript has developed a NLS-Cas9-NLS nuclease which contains a nuclear localization sequence (NLS) on both ends of the protein to meet all the researchers’ requirements (e.g. in vitro cleavage assay, RNP complex transfection, and micro injection).

Product Source: GenCrispr NLS-Cas9-NLS is produced by expression in an E. coli strain carrying a plasmid encoding the Cas9 gene from Streptococcus pyogenes with a nuclear localization signal (NLS) on both ends.

Key Features

-DNA-free: no external DNA added to system

-High cleavage efficiency: Double NLS ensures the efficient entry of Cas9 protein into nuclei

-Low off target: transient expression of Cas9 nuclease

Time-saving: no need for transcription and translation

Applications

-Screening for highly efficient and specific targeting gRNAs by in vitro DNA cleavage.

–In vivo gene editing when combined with a specific gRNA by electroporation or injection.

Cas9 nuclease is an RNA-guided endonuclease that can catalyze cleavage of double stranded DNA. This kind of targeted nuclease is a powerful tool for genome editing with high precision. Cas9 protein forms a very stable ribonucleoprotein (RNP) complex with the guide RNA (gRNA) component of the CRISPR/Cas9 system. The Cas9 RNP complex can localize to the nucleus immediately upon entering the cell with the addition of a nuclear localization signal (NLS). There is no requirement for transcription and translation compared with mRNA or plasmid systems. Additionally, the Cas9 RNP complex is rapidly cleared from the cell minimizing the chance of off-target cleavage when compared to other systems (Kim, et al. 2014). This DNA-free system avoids the risk of inserting foreign DNA into the genome, which can be quite useful for gene editing-based disease therapy. GenScript has developed a NLS-Cas9-NLS nuclease which contains a nuclear localization sequence (NLS) on both ends of the protein to meet all the researchers’ requirements (e.g. in vitro cleavage assay, RNP complex transfection, and micro injection).

Product Source: GenCrispr NLS-Cas9-NLS is produced by expression in an E. coli strain carrying a plasmid encoding the Cas9 gene from Streptococcus pyogenes with a nuclear localization signal (NLS) on both ends.

Key Features

-DNA-free: no external DNA added to system

-High cleavage efficiency: Double NLS ensures the efficient entry of Cas9 protein into nuclei

-Low off target: transient expression of Cas9 nuclease

Time-saving: no need for transcription and translation

Applications

-Screening for highly efficient and specific targeting gRNAs by in vitro DNA cleavage.

–In vivo gene editing when combined with a specific gRNA by electroporation or injection.

The
clustered regularly interspaced short palindromic repeats, known as CRISPR  systems are adaptive immune mechanisms commonly
present in archaea and bacteria. The CRISPR systems enable the host to specifically
target and cleave foreign nucleic acids thus targeting infectiousviruses and
plasmids. Recently, a type V CRISPR system has been identified in several
bacteria, the Cpf1 CRISPR from Prevotella and Francisella 1. In contrast to
Cas9 systems, CRISPR/Cpf1 systems are smaller in size, do not require an
additional trans-activating crRNA (tracrRNA), and allow for targeting of
additional genomic regions by cleaveing the target DNA proceeded by a short
T-rich protospacer-adjacent motif (PAM). On the other hand, the Cas9 system requires
a G-rich PAM following the target DNA. Furthermore, Cas12a/Cpf1 introduces a
staggered DNA double stranded break with a 4 or 5-nt 5’ overhang. Recombinant
Acidaminococcus sp. BV3L6 Cas12a (cpf1) nuclease is expressed in E. coli and
purified. The nuclease contains nuclear localization sequence (NLS) at the
C-terminus and 6× His-tag at the C-terminus.

The
clustered regularly interspaced short palindromic repeats, known as CRISPR  systems are adaptive immune mechanisms commonly
present in archaea and bacteria. The CRISPR systems enable the host to specifically
target and cleave foreign nucleic acids thus targeting infectiousviruses and
plasmids. Recently, a type V CRISPR system has been identified in several
bacteria, the Cpf1 CRISPR from Prevotella and Francisella 1. In contrast to
Cas9 systems, CRISPR/Cpf1 systems are smaller in size, do not require an
additional trans-activating crRNA (tracrRNA), and allow for targeting of
additional genomic regions by cleaveing the target DNA proceeded by a short
T-rich protospacer-adjacent motif (PAM). On the other hand, the Cas9 system requires
a G-rich PAM following the target DNA. Furthermore, Cas12a/Cpf1 introduces a
staggered DNA double stranded break with a 4 or 5-nt 5’ overhang. Recombinant
Acidaminococcus sp. BV3L6 Cas12a (cpf1) nuclease is expressed in E. coli and
purified. The nuclease contains nuclear localization sequence (NLS) at the
C-terminus and 6× His-tag at the C-terminus.

The
clustered regularly interspaced short palindromic repeats, known as CRISPR  systems are adaptive immune mechanisms commonly
present in archaea and bacteria. The CRISPR systems enable the host to specifically
target and cleave foreign nucleic acids thus targeting infectiousviruses and
plasmids. Recently, a type V CRISPR system has been identified in several
bacteria, the Cpf1 CRISPR from Prevotella and Francisella 1. In contrast to
Cas9 systems, CRISPR/Cpf1 systems are smaller in size, do not require an
additional trans-activating crRNA (tracrRNA), and allow for targeting of
additional genomic regions by cleaveing the target DNA proceeded by a short
T-rich protospacer-adjacent motif (PAM). On the other hand, the Cas9 system requires
a G-rich PAM following the target DNA. Furthermore, Cas12a/Cpf1 introduces a
staggered DNA double stranded break with a 4 or 5-nt 5’ overhang. Recombinant
Acidaminococcus sp. BV3L6 Cas12a (cpf1) nuclease is expressed in E. coli and
purified. The nuclease contains nuclear localization sequence (NLS) at the
C-terminus and 6× His-tag at the C-terminus.

The
clustered regularly interspaced short palindromic repeats, known as CRISPR  systems are adaptive immune mechanisms commonly
present in archaea and bacteria. The CRISPR systems enable the host to specifically
target and cleave foreign nucleic acids thus targeting infectiousviruses and
plasmids. Recently, a type V CRISPR system has been identified in several
bacteria, the Cpf1 CRISPR from Prevotella and Francisella 1. In contrast to
Cas9 systems, CRISPR/Cpf1 systems are smaller in size, do not require an
additional trans-activating crRNA (tracrRNA), and allow for targeting of
additional genomic regions by cleaveing the target DNA proceeded by a short
T-rich protospacer-adjacent motif (PAM). On the other hand, the Cas9 system requires
a G-rich PAM following the target DNA. Furthermore, Cas12a/Cpf1 introduces a
staggered DNA double stranded break with a 4 or 5-nt 5’ overhang. Recombinant
Acidaminococcus sp. BV3L6 Cas12a (cpf1) nuclease is expressed in E. coli and
purified. The nuclease contains nuclear localization sequence (NLS) at the
C-terminus and 6× His-tag at the C-terminus.

GenCRISPR Cas13a (C2c2) Nuclease is an RNA-guided, RNA-targeting CRISPR enzyme, commonly referred to as C2c2. This enzyme is a member of Type VI CRISPR family containing a single protein effector with two HEPN domains. The Cas13a exhibits two RNase activities. The first activity, a cis- sequence-specific RNA guided cleavage, activates the secondary RNase activity of the enzyme, a non-specific trans- ribonuclease activity. This Cas13a protein can be applied to detect single RNA molecules with proven high specificity.

GenCRISPR Cas13a (C2c2) Nuclease is an RNA-guided, RNA-targeting CRISPR enzyme, commonly referred to as C2c2. This enzyme is a member of Type VI CRISPR family containing a single protein effector with two HEPN domains. The Cas13a exhibits two RNase activities. The first activity, a cis- sequence-specific RNA guided cleavage, activates the secondary RNase activity of the enzyme, a non-specific trans- ribonuclease activity. This Cas13a protein can be applied to detect single RNA molecules with proven high specificity.

GenCRISPR Cas13a (C2c2) Nuclease is an RNA-guided, RNA-targeting CRISPR enzyme, commonly referred to as C2c2. This enzyme is a member of Type VI CRISPR family containing a single protein effector with two HEPN domains. The Cas13a exhibits two RNase activities. The first activity, a cis- sequence-specific RNA guided cleavage, activates the secondary RNase activity of the enzyme, a non-specific trans- ribonuclease activity. This Cas13a protein can be applied to detect single RNA molecules with proven high specificity.

The GenCRISPR™
Cas9 v1.1 can be formed
with the guide RNA into a ribonucleoprotien (RNP) complex. The use of an RNP
complex to perform gene editing has been shown to reduce the challenges
encountered with other CRISPR gene editing techniques such as viral and plasmid
delivery. Challenges include off-target effects, cell viability and transcription/translational
challenges.

GenCRISPR™
Cas9 v1.1 is a tag free nuclease produced by expression in an E. coli strain carrying a plasmid
encoding the Cas9 gene from Streptococcus
pyogenes with a biparticle nucleus localization signal (BPNLS) at both
N-terminal and C-terminal. It has been reported that BPNLS is able to improve
the gene editing efficiency.

The GenCRISPR™
Cas9 v1.1 can be formed
with the guide RNA into a ribonucleoprotien (RNP) complex. The use of an RNP
complex to perform gene editing has been shown to reduce the challenges
encountered with other CRISPR gene editing techniques such as viral and plasmid
delivery. Challenges include off-target effects, cell viability and transcription/translational
challenges.

GenCRISPR™
Cas9 v1.1 is a tag free nuclease produced by expression in an E. coli strain carrying a plasmid
encoding the Cas9 gene from Streptococcus
pyogenes with a biparticle nucleus localization signal (BPNLS) at both
N-terminal and C-terminal. It has been reported that BPNLS is able to improve
the gene editing efficiency.

The GenCRISPR™
Cas9 v1.1 can be formed
with the guide RNA into a ribonucleoprotien (RNP) complex. The use of an RNP
complex to perform gene editing has been shown to reduce the challenges
encountered with other CRISPR gene editing techniques such as viral and plasmid
delivery. Challenges include off-target effects, cell viability and transcription/translational
challenges.

GenCRISPR™
Cas9 v1.1 is a tag free nuclease produced by expression in an E. coli strain carrying a plasmid
encoding the Cas9 gene from Streptococcus
pyogenes with a biparticle nucleus localization signal (BPNLS) at both
N-terminal and C-terminal. It has been reported that BPNLS is able to improve
the gene editing efficiency.

The GenCRISPR™
Cas9 v1.2 can be formed
with the guide RNA into a ribonucleoprotien (RNP) complex. The use of an RNP
complex to perform gene editing has been shown to reduce the challenges
encountered with other CRISPR gene editing techniques such as viral and plasmid
delivery. Challenges include off-target effects, cell viability and transcription/translational
challenges.

GenCRISPR™ Cas9 v1.2 is a tag
free nuclease produced by expression in an E.
coli strain carrying a plasmid encoding the Cas9 gene from Streptococcus pyogenes with a biparticle
nucleus localization signal (BPNLS) at N-terminal and a nucleoplasmin nucleus
localization signal (nucleoplasmin NLS) at C-terminal. It has been reported
that BPNLS and nucleoplasmin NLS are able to improve the gene editing
efficiency. 

The GenCRISPR™
Cas9 v1.2 can be formed
with the guide RNA into a ribonucleoprotien (RNP) complex. The use of an RNP
complex to perform gene editing has been shown to reduce the challenges
encountered with other CRISPR gene editing techniques such as viral and plasmid
delivery. Challenges include off-target effects, cell viability and transcription/translational
challenges.

GenCRISPR™ Cas9 v1.2 is a tag
free nuclease produced by expression in an E.
coli strain carrying a plasmid encoding the Cas9 gene from Streptococcus pyogenes with a biparticle
nucleus localization signal (BPNLS) at N-terminal and a nucleoplasmin nucleus
localization signal (nucleoplasmin NLS) at C-terminal. It has been reported
that BPNLS and nucleoplasmin NLS are able to improve the gene editing
efficiency.